Evidence-based incorporation of key parameters into MELD score for acute-on-chronic liver failure.

eGastroenterology

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhej

Published: September 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The model for end-stage liver disease (MELD) score is widely used for the prognostication in end-stage liver disease but has limited performance in acute-on-chronic liver failure (ACLF). In this study, we identified additional predictive parameters and reformed the MELD score to predict ACLF more accurately.

Methods: A meta-analysis was performed on relevant studies to identify the predictive factors of 28-day/90-day outcomes of ACLF, which were validated in two large prospective cohorts. A prognostic score was developed by incorporating predictive parameters into the MELD score. The model was evaluated with a focus on discrimination and calibration.

Results: The meta-analysis incorporated 32 cohort studies with a total of 13 939 patients, of which 13 risk factors were identified, and 3 risk factors (age, neutrophil count and hepatic encephalopathy (HE) grade) besides MELD score were validated in 751 patients with ACLF derived from two prospective cohorts. A new model (Chinese Acute-on-Chronic Liver Failure Consortium (CATCH-LIFE)-MELD score) was developed as follows: 0.028×age+0.3×HE grade+0.039×neutrophil count+0.079×MELD score. CATCH-LIFE-MELD score achieved a concordance index of 0.791/0.788 for 28-day/90-day outcomes, which is superior to other traditional scores. Other discrimination indices, including net reclassification improvement, integrated discrimination improvement and probability density function, and calibration including Nagelkerke's R and Brier scores confirmed its superiority. Moreover, the accuracy of CATCH-LIFE-MELD score remained stable. It was highest in patients with or without hepatitis B virus infection, cirrhosis, liver failure or under the Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria or European Association for the Study of the Liver (EASL) criteria. All results were substantiated by an evaluation using an external cohort.

Conclusions: CATCH-LIFE-MELD score, a modified MELD score exhibited improved accuracy in predicting the short-term prognosis of ACLF than other traditional scores.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770428PMC
http://dx.doi.org/10.1136/egastro-2024-100101DOI Listing

Publication Analysis

Top Keywords

meld score
24
liver failure
16
catch-life-meld score
16
score
12
acute-on-chronic liver
12
parameters meld
8
end-stage liver
8
liver disease
8
predictive parameters
8
28-day/90-day outcomes
8

Similar Publications

This research has proposed a new Emotion Recognition in Conversation (ERC) model known as Hierarchical Graph Learning for Emotion Recognition (HGLER), built to go beyond the existing approaches that find it difficult to request long-distance context and interaction across different data types. Rather than simply mixing different kinds of information, as is the case with traditional methods, HGLER uses a 2-part graph technique whereby conversations are represented in a 2-fold manner: one aimed at illustrating how various parts of the conversation relate and another for enhancing learning from various types of data. This dual-graph system can represent multimodal data value for value by exploiting the benefits of each type of data yet tracking their interactions.

View Article and Find Full Text PDF

Background: Steatotic liver diseases (SLDs) and their subcategories-metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD)-significantly contribute to liver-related and extrahepatic morbidity and mortality. This project aimed to assess the landscape of SLDs and clinically significant fibrosis (CSF) before (2017-2020) and during (2021-2023) the COVID-19 pandemic.

Methods: Using National Health and Nutrition Examination Survey (NHANES) data, we analyzed 8965 prepandemic and 6337 pandemic participants aged ≥18 years.

View Article and Find Full Text PDF

Introduction: Oral nucleos(t)ide analogues (NAs) are widely used in managing hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Among first-line therapies, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are commonly prescribed. However, their comparative efficacy and safety remain unclear in HBV-ACLF.

View Article and Find Full Text PDF

Background: Liver transplantation (LT) is a life-saving procedure for end-stage liver disease (ESLD), yet massive perioperative transfusions (MT) remain a significant concern. The McCluskey Risk Index (McRI), a widely used tool for predicting MT, was developed nearly two decades ago and does not fully account for recent advancements in LT practices and patient demographics. This study aims to evaluate the validity of the McRI in a contemporary LT cohort and propose a revised McRI (revMcRI) incorporating additional predictors.

View Article and Find Full Text PDF

Background And Aims: The MELD score assesses liver disease severity and guides liver allocation in the United States. This study aims to address the knowledge gap regarding potential disparities in the performance of MELD-Na and MELD 3.0 scores across races and ethnicities.

View Article and Find Full Text PDF